R&D News | pharmaphorum

News

Braveheart, AAVantgarde rounds head recent biofinancings

Our latest crop of biotech financings has nine-figure rounds for Braveheart and AAVantgarde, with Azalea Therapeutics and NEOK Bio also raising funds.

News

Lilly reports 20% weight loss with amylin-targeting drug

Eli Lilly has raised the stakes in the obesity market with positive midstage data for its amylin-targeting drug eloralintide.

News

Novo Nordisk fights back with oral GLP-1 data in obesity

Shortly after reporting weaker sales growth for its injectable GLP-1 drugs, Novo Nordisk has new data to help it stake a claim to the oral market.

News

Pfizer said to have matched Novo's $10bn bid for Metsera

The battle for obesity drug developer Metsera rumbles on, with Pfizer reported to have now matched Novo Nordisk's $10 billion offer.

News

Psychedelic merger to create AtaiBeckley completes

A $390m merger of two pioneers of psychedelic medicines has completed to create AtaiBeckley, with a pipeline of candidates for mental illnesses.

News

UK facing alarming loss of scientific talent overseas

Two new reports suggest the UK is seeing an exodus of skilled STEM workers to other countries, placing the country's economic future at risk.

Braveheart, AAVantgarde rounds head recent biofinancings

Lilly reports 20% weight loss with amylin-targeting drug

Novo Nordisk fights back with oral GLP-1 data in obesity

Pfizer said to have matched Novo's $10bn bid for Metsera

Psychedelic merger to create AtaiBeckley completes

UK facing alarming loss of scientific talent overseas

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks